In this report, we describe a patient with CALR-positive post-ET myelofibrosis treated with intermittent Hu (20 mg/Kg, given as a single dose, thrice weekly) [13], achieving effective disease control, including regression of bone marrow fibrosis from grade 3 to grade 1 [14]. This evidence concerns the gene CALR and myelofibrosis.